BMS-986500 + palbociclib + fulvestrant

This is an experimental combination therapy comprising **BMS-986500** (a small molecule investigational inhibitor, possibly targeting cyclin-dependent kinases), **palbociclib** (a selective CDK4/6 inhibitor), and **fulvestrant** (an estrogen receptor antagonist and degrader). The drug combination is being studied in advanced solid tumors, including advanced breast cancer and ovarian cancer, specifically in patients previously treated with CDK4/6 inhibitors. BMS-986500 is being developed by Bristol Myers Squibb and, in combination, aims to overcome resistance to prior CDK4/6 inhibition and hormone therapy[1][2][3][4][5][6].